Semax and Selank: what the studies found
Reviewed 38 sourcesPublished by PepVault
Semax and Selank are Russian nasal-drop peptides with no FDA approval. Every PubMed human study of each, with its size, its design and what it measured.

- Last reviewed
- Sources
- 38
- Questions
- 10
- Compounds
- 2
The short answer
Semax and Selank are short lab-made peptides, seven amino acids each, sold in Russia as nasal drops: Semax since 1994, on prescription, for stroke and memory problems, and Selank since 2009, without one, for anxiety. Neither is approved by the FDA or in the EU. Their human record is a set of small Russian studies; the only placebo-controlled ones are brain-scan studies of 24 and 52 healthy volunteers.
Evidence: Human evidence: small Russian studies, most without a placebo group and published in Russian; the only placebo-controlled studies measured brain scans in healthy volunteers. How they work comes from rats, mice and lab dishes.

What are Semax and Selank?
Both are heptapeptides, chains of seven amino acids, built in Moscow from a piece of a natural molecule plus the same three-amino-acid tail, Pro-Gly-Pro1. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) starts from ACTH 4-7, a fragment of the pituitary hormone ACTH35; its Russian label calls it an ACTH analogue with no hormonal activity5. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) starts from tuftsin, a four-amino-acid immune peptide, and the tail makes it resist the enzymes that cut peptides apart34.
In Russia, Semax is labelled for memory and thinking problems after vascular brain disease, stroke recovery, brain injury and optic nerve disease, and in children from age 7 for attention problems, including ADHD5. Selank is labelled for anxiety, neurasthenia (a state of lasting fatigue and irritability) and stress-related disorders6. Both come as drops for the nose; Semax needs a prescription and Selank does not56.

Are Semax and Selank approved anywhere?
Only in Russia. The registry records, as copied by Russia's RLS drug reference, give these dates:
| Product | First registered | Holder | Current record |
|---|---|---|---|
| Semax 0.1% nasal drops | December 20, 19943 (that record has expired) | Institute of Molecular Genetics, Russian Academy of Sciences; Peptogen today5 | Re-registered March 26, 20255 |
| Semax 1% nasal drops | December 29, 20114 | Peptogen | Number Р N000812/01, no end date4 |
| Selank 0.15% nasal drops | 2009 (number ЛСР-003338/09)6 | Peptogen | Re-registered July 15, 20256 |
In the United States, Drugs@FDA lists no application for either one29. In July 2026, FDA's staff took Semax to its Pharmacy Compounding Advisory Committee and recommended against adding it to the list of substances pharmacies may compound, citing missing quality data, too little safety information and too little evidence that it works2. The committee met on July 2426, and on October 30, 2026 HHS published a draft policy: until a final rule decides, it does not intend to act against pharmacies that compound Semax, as a nasal product on a prescription3738. That is not an approval, and the policy binds no one37. Neither peptide appears in the European Medicines Agency's register of authorised medicines27.
How does a nasal peptide reach the brain?
The label route is intranasal: drops into each nostril, absorbed through the lining of the nose56. In rats given a tritium-tagged Semax in the nose, 0.093% of the dose per gram of brain tissue was in the brain two minutes later, and the peptide broke down fast, mostly into its Pro-Gly-Pro tail24. In mice, Selank given in the nose and Selank injected into the belly changed different brain receptors, so the route changed the effect28.
Species note: both findings come from rodents. FDA found no study of how Semax is absorbed or cleared in people, by any route2.
Add Semax or Selank from the PepVault library and it is set up as a nasal spray: each dose logs with one tap, with no injection site to record. Log it in PepVault
What did the Semax studies in people measure?
These are the human studies of Semax indexed in PubMed with a size in the abstract, or in FDA's 2026 review where the abstract gives none2. Most are in Russian with an English abstract.
| Study | Who | Size | Design | What it found |
|---|---|---|---|---|
| Gusev 19977 | Acute ischemic stroke | 30, against 80 on usual care | Added to usual care, no placebo | Faster recovery of motor and other deficits |
| Gusev 20058 | Reduced blood flow to the brain | 187 | Design not given in the abstract | Clinical improvement, fewer strokes and mini-strokes, few side effects |
| Gusev 20189 | After ischemic stroke, in rehab | 110 | With and without Semax, 5 months | Blood BDNF rose and stayed high; daily function (Barthel score) improved faster |
| Serdiuk 200710 | Motor neuron disease | 27 | Open-label, no control | No change in disease course; quality of life better, best at day 10 |
| Alekseeva 199911 | Lasting brain damage from oxygen loss | 73 | No control described | Helped memory problems; seizure-like EEG bursts in some |
| Ivanikov 200212 | Peptic ulcers that would not heal | 322 | Added to ulcer drugs, against ulcer drugs alone | Healed by day 14: 89.5% against 30.8% |
| Nazarova 201313 | Diabetic eye disease | 114 | Three groups, two with Semax | Better vision tests with Semax |
| Dontsova 201536 | Psoriasis with metabolic syndrome | 118 (60 Semax, 58 usual care) | Added to usual treatment, 10 days | Blood cholesterol and triglycerides fell; no change on usual care alone |
| Koroleva 199616 | Migraine and facial nerve pain | 372 | One dose, no control | Migraine pain stopped in 4 of 122 |
| Lebedeva 201814 | Healthy volunteers | 24 (14 Semax, 10 placebo) | One nasal dose against placebo | A resting brain network on MRI grew in its front part |
| Panikratova 202015 | Healthy volunteers | 52 | One dose of Semax, Selank or placebo | Changed connections of the amygdala, an emotion region |
Other papers in optic nerve disease, glaucoma and eye surgery give no size in their abstracts or pair Semax with physiotherapy, so they cannot show what Semax did alone303132. FDA also counted 451 children, with depression or with tics, in two studies where Semax was given with other treatments; it found the full reports unavailable2.
What did the Selank studies in people measure?
Selank's human record in PubMed is four clinical papers and the shared brain-scan study. All compare it with a benzodiazepine (a standard anti-anxiety drug) or with nothing; none has a placebo group.
| Study | Who | Size | Design | What it found |
|---|---|---|---|---|
| Zozulia 200817 | Generalized anxiety disorder and neurasthenia | 62 (30 Selank, 32 medazepam) | Against medazepam | Similar anxiety relief; Selank also eased fatigue |
| Medvedev 201418 | Anxiety and somatoform disorders | 60 | Against phenazepam | Clear anxiety relief and a mild effect on thinking, lasting a week after the last dose |
| Medvedev 201519 | Anxiety disorders | 70 (30 phenazepam alone, 40 with Selank) | Added to phenazepam | Phenazepam worked sooner, with fewer of its side effects such as sleepiness and memory lapses |
| Uchakina 200820 | Anxiety with fatigue | Not given | 14 days, blood tests | Shifts in immune signalling molecules (cytokines) |
| Panikratova 202015 | Healthy volunteers | 52 | One dose against placebo | Changed connections of the amygdala |
How strong is the evidence for Semax and Selank?
Thin, and the tables show why. Across both peptides, the only studies with a placebo group are the two brain-scan studies, and they measured scans in healthy people over 20 minutes, not symptoms1415. No abstract above says the patients were randomized or that anyone was blinded. The largest studies, of 187, 118 and 114 people, do not say how patients were put into groups83613.
Most of the Selank papers and several Semax papers list N. F. Myasoedov, of the Institute of Molecular Genetics that holds Semax's first registration, among their authors371719. ClinicalTrials.gov holds no registered trial of either peptide33. When FDA reviewed Semax in 2026, it set aside the Russian-language stroke papers because no English translation was supplied, and judged the evidence insufficient for stroke, migraine and facial nerve pain2. A 2021 US review called Selank a poorly studied Russian drug25.
What do the animal studies show?
Most of what is said about how these peptides work comes from rodents. In rats, one dose of Semax raised BDNF, a growth signal for nerve cells, by up to 1.4-fold in the hippocampus, the memory region21. In rats, Selank changed the activity of 45 of 84 genes tied to nerve signalling within an hour, in a pattern that tracked GABA, the brain's main calming signal23. In human blood serum in a lab dish, both slowed the enzymes that break down enkephalins, the body's own pain-and-mood peptides1.
Species note: the BDNF and gene results are from rats; the enzyme result is from serum in a dish, not from people taking the drug.
Is Semax a stimulant?
Not in the usual sense: on its own, Semax did not change dopamine levels in rodents22. Given 20 minutes before amphetamine, though, it sharply increased amphetamine's dopamine release and activity in rodents22, a finding FDA singled out as a concern2. Its Russian label files it under "other psychostimulants and nootropics" (ATC code N06BX) and lists anxiety disorders and acute mental states among the reasons not to use it5.
Is Selank or Semax better?
They were built for different jobs, so the studies cannot rank them. Semax's patients had strokes, brain injuries or eye disease7913; Selank's had anxiety1718. The one study that gave both, to healthy volunteers, found shared and separate effects on amygdala connections, measured on a scan rather than in how people felt15. No study has tested them taken together.
Commonly reported: of 31 people whose open write-ups on Semax we counted, 22 described an effect they wanted, most often clearer, quicker thinking; 4 described one they did not, such as the effect fading, worse sleep or irritability. Of 22 people writing about Selank, 19 described a wanted effect, most often feeling calmer.
What side effects do the labels list?
Semax's Russian label lists mild irritation of the nose lining with long use5. Selank's lists allergic reactions in people sensitive to it and an unpleasant taste when drops run into the throat6. Both labels rule out pregnancy and breastfeeding; Selank's also rules out anyone under 18, and Semax's anyone under 756. Most of the Semax studies FDA reviewed did not report side effects at all2.
Give each dose a time and switch on its reminder, and PepVault sends a push shortly after that time if it is still unlogged; a note on each log keeps what you noticed beside the dose. Set reminders in PepVault
When to get help Semax's label lists a history of seizures as a reason not to use it, and FDA raised a bleeding question from clotting data in rats, so anyone with seizures or on a blood thinner should talk to a clinician first2511.
Sources
- Kost NV et al. Semax and Selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001. PubMed 11443939
- FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026: FDA briefing document for Semax-related bulk drug substances (evaluation dated May 11, 2026). fda.gov
- RLS drug reference, registration record 94/294/10: Semax solution 0.1%, nasal drops, registered December 20, 1994 (holder: Institute of Molecular Genetics, Russian Academy of Sciences). rlsnet.ru
- RLS drug reference, registration record Р N000812/01: Semax 1% nasal drops, registered December 29, 2011 (holder: Peptogen). rlsnet.ru
- Vidal Russia. Semax 0.1% nasal drops: registration ЛП-№(009449)-(РГ-RU) of March 26, 2025, and the label (indications, contraindications, side effects). vidal.ru
- Vidal Russia. Selank 0.15% nasal drops: registration ЛП-№(010951)-(РГ-RU) of July 15, 2025 (previous ЛСР-003338/09), and the label. vidal.ru
- Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997. PubMed 11517472
- Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. PubMed 15792140
- Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 29798983
- Serdiuk AV et al. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zh Nevrol Psikhiatr Im S S Korsakova. 2007. PubMed 18379501
- Alekseeva GV et al. Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesteziol Reanimatol. 1999. PubMed 10199046
- Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bull Exp Biol Med. 2002. PubMed 12459874
- Nazarova GA et al. The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy. Vopr Kurortol Fizioter Lech Fiz Kult. 2013. PubMed 24437205
- Lebedeva IS et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018. PubMed 30225715
- Panikratova YR et al. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci. 2020. PubMed 32342318
- Koroleva MV et al. Study of the analgesic effect of the semax preparation. Biull Eksp Biol Med. 1996. PubMed 8998343
- Zozulia AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18454096
- Medvedev VE et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PubMed 25176261
- Medvedev VE et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PubMed 26356395
- Uchakina ON et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18577961
- Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006. PubMed 16996037
- Eremin KO et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005. PubMed 16362768
- Volkova A et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016. PubMed 26924987
- Shevchenko KV et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim. 2006. PubMed 16523722
- Doyno CR, White CM. Sedative-hypnotic agents that impact gamma-aminobutyric acid receptors: focus on flunitrazepam, gamma-hydroxybutyric acid, phenibut, and selank. J Clin Pharmacol. 2021. PubMed 34396551
- FDA. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (meeting page). fda.gov
- European Medicines Agency. Medicines for human use: the full report of authorised medicines (searched November 20, 2026). ema.europa.eu
- Vasil'eva EV et al. Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksp Klin Farmakol. 2016. PubMed 29787664
- FDA. Drugs@FDA, searched through the openFDA drugsfda endpoint for semax and selank on November 20, 2026: no matches. api.fda.gov
- Polunin GS et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000. PubMed 10741256
- Kurysheva NI et al. Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Vestn Oftalmol. 2001. PubMed 11569188
- Yusef Y et al. Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation. Vestn Oftalmol. 2026. PubMed 42885627
- ClinicalTrials.gov API v2, intervention searches for semax and selank on November 20, 2026: no trial of either peptide. clinicaltrials.gov
- Semenova TP et al. Experimental optimization of learning and memory processes by selank. Eksp Klin Farmakol. 2010. PubMed 20919548
- Filippenkov IB et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes (Basel). 2020. PubMed 32580520
- Dontsova EV. Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Eksp Klin Farmakol. 2015. PubMed 27051926
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026. federalregister.gov
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (draft, October 2026). hhs.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.